Skip to content


Calliditas leverages considerable experience in drug development and proprietary formulation expertise to selectively explore treatments for orphan diseases in which there is strong rationale and high unmet need. To that end, we seek to maximize the potential of our products by commercializing on a standalone basis in the United States market and through strategic partnerships in other regions. Additionally, we are interested in enhancing our product portfolio by identifying and in-licensing additional, late-stage product candidates that are a strong strategic and commercial fit.

Interim Report Q3 2023

On November 7, 2023, at 07:00 CET, Calliditas Therapeutics published its Interim Report for Q3 2023. 

Webcast: at 14:30 p.m. CET the same day. 

IR Contact

Åsa web photo (1)

Åsa Hillsten

Head of IR and Sustainability